• The Journal of Pediatrics of Korean Medicine
• /
• v.18 no.2
• /
• pp.49-59
• /
• 2004

Objective : The purpose of this study is to demonstrate the therapeutic effect of oriental treatment on Acute Myelogenous Leukemia. Methods : The patient was treated by Acupuncture, Indirect Moxibustion, Herb Medicine (Seogakjihwangtang-gamibang), and had significant improvement in the Acute Myelogenous Leukemia. Results : 1. Acute Leukemia is one of the most common malignant neoplasm of pediatrics, and is chracterised by anemia, infections, bleeding, debility, paleness, fever, anorexia, lymphoadenia, hepatomegaly, splenomegaly, etc. 2. The management of Acute Myelogenous Leukemia consists of the challenge of optimizing chance for prolonged remission and cure, while minimizing the toxicity to the patients. Therefore oriental medical treatment may be useful for this. 3. We experienced a case of the 10-year-old male patient with Acute Myelogenous Leukemia, after oriental medical treatment his chief symptoms(anemia, bleeding, purpura, debility, paleness, fever, anorexia, insomnia, etc)and general condition were improved. Conclusion : A 10-year-old male patient with Acute Myelogenous Leukemia, after oriental medical treatment his chief symptoms and general condition were improved. This oriental medical treatment may be possible or effective in Acute Myelogenous Leukemia. The more clinical study about oriental medical treatment on Acute Myelogenous Leukemia will be needed.

• The Korean Journal of Pain
• /
• v.13 no.1
• /
• pp.119-122
• /
• 2000

Granulocytic sarcoma (chloroma) is a rare, solid tumor of myelogenous stem cells, shows usually in patients with acute myelogenous leukemia and less commonly in patients with chronic myelogenous leukemia or myeloproliferative disorders. We report here a patient presenting acute paraparesis due to spinal epidural granulocytic sarcoma causing spinal cord compression in acute myelogenous leukemia with a brief review of literature.

• Journal of Korean Neurosurgical Society
• /
• v.29 no.11
• /
• pp.1533-1537
• /
• 2000

Granulocytic sarcomas are solid tumors resulting from the localized proliferation of myelogenous leukions cells. Epidural involvement of granulocytic sarcoma is very rare in acute myelogenous leukemia(AML). We report a patient with a thoracic epidural granulocytic sarcoma whose presentation with acute paraparesis led to the diagnosis of relapsing of alleged AML. Early recognition of the etiology of the paraparesis and treatment with emergency decompressive, laminectomy, radiation therapy and chemotherapy resulted in an excellent neurological and hematological outcome.

• The Korean Journal of Nuclear Medicine
• /
• v.1 no.2
• /
• pp.35-39
• /
• 1967

Ferrokinetcs by Pollycove's method on 2 cases of Chronic myelogenous leukemia were presented in order to study the erythropoietic function and pathogenesis of anemia. The results are as follows. (1) The daily hemoglobin syntheses were slightly elevated. Both the mean effective hemoglobinization time and mean erythron life span were shortened. The maximum net ROC incorporations of $^{59}Fe$ weere decreased. The in vivo surface measurements of radioactivity over liver, spleen, and sacral bone marrow revealed findings consistant with hemolysis and extramedullary hematopoies. (2) Based upon those findings it is assumed that anemia in chronic myelogenous leukemia may result from hemolysis and inadequate compensation to the developing anemia.

• BMB Reports
• /
• v.35 no.4
• /
• pp.377-383
• /
• 2002

Arsenic trioxide ($As_O_3$) was recently demonstrated to be an effective inducer of apoptosis in patients with relapsed acute promyelocytic leukemia (APL) as well as patients with APL in whom all-trans-retinoic acid and conventional chemotherapy failed. Chronic myelogenous leukemia cells are highly resistant to chemotherapeutic drugs. To determine if $As_O_3$ might be useful for the treatment of chronic myelogenous leukemia, we examined the ability of $As_O_3$ to induce apoptosis in K562 cells. In vitro cytotoxicity of $As_O_3$ was evaluated in K562 cells by a MTT assay: the $IC_50$ value for $As_O_3$ was determined to be $10\;{\mu}m$. When analyzed by agarose gel electorphoresis, the DNA fragments became evident after incubation of the cells with $20\;{\mu}m$ $As_O_3$ for 24 h. We also found morphological changes and chromatin condensation of the cells undergoing apoptosis. Activation of caspase-3 was observed 6 h after treatment with $20\;{\mu}m$ $As_O_3$ by a Western blot analysis. Next, we examined the MAP kinase-signaling pathway of $As_O_3$-induced apoptosis in K562 cells. $As_O_3$ at $10\;{\mu}m$ strongly induced the activation of p38, inhibited $As_O_3$ induced apoptotic cell death. These results suggest that $As_O_3$ is able to induce the apoptotic activity in K562 cells, and its apoptotic mechanism may be associated with the activation of p38.

• Korean Journal of Community Nutrition
• /
• v.7 no.4
• /
• pp.578-584
• /
• 2002

This study was designed to investigate the association between the period of engraftment and the nutritional status of patient s undergoing bone marrow transplantation for acute myelogenous leukemia (AML). Nutritional status was evaluated by body mass index (BMI), percentage of ideal body weight (PIBW), percentage of weight loss, and serum albumin, total protein (T protein), hemoglobin (HGB) and hematocrit (HCT) levels on the day prior to transplantation and on the day of bone marrow transplantation. The periods of engraftment were determined by absolute neutrophil counts (ANC) above $500/mm^3$ from the day of bone marrow transplantation. The study subjects were 80 patients (55 males, 25 females) with acute myelogenous leukemia admitted to the University Hospital in Seoul. The result of this study is as follows : Tie nutritional status values of the majority of patients on the day prior to transplantation were in the normal range except for HGB and HCT ; however, during hospitalization, all of the levels of the nutritional status values were significantly decreased. The periods of engraftment of the abnormal group according to their BMI, PIBW, HGB and HCT levels on the day of bone marrow transplantation showed no difference when compared to the normal group. However, the periods of engraftment of the abnormal group, according to the percentage of weight loss, albumin, and T protein levels were significantly decreased when compared to the normal group. Therefore, the nutritional status of patients at the time of transplant had a noticeable influence on the periods of engraftment. Our results suggested that nutritional status is a critical factor of engraftment in BMT during pre-transplant and post-transplant. Futhermore, we recommend that the process of nutritional preparation for the transplant should initiate immediately after the transplant decision has been made.

• The Korean Journal of Nuclear Medicine
• /
• v.32 no.5
• /
• pp.436-442
• /
• 1998

Radioactive iodine treatment has been widely used for nearly 50 years in the treatment of thyroid cancer to ablate residual thyroid tissue after thyroidectomy and to treat metastatic disease. Leukemia is a rare complication associated with the radioactive iodine therapy. The occurrence of leukemia is known to be related to the cumulative dosage of I-131 more than 37 GBq (1 Ci) and also associated with the intervals of less than 12 months between the repeated doses. We report a case of a 52 year-old female patient with papillary cancer of thyroid who developed acute myelogenous leukemia after the total 20.4 GBq (550 mCi) of I-131 therapy over 3.2 years and palliative radiation therapy (3000 cGy) due to multiple bone metastasis of papillary cancer.

• BMB Reports
• /
• v.38 no.6
• /
• pp.725-738
• /
• 2005

Resistance to imatinib mesylate (also known as Gleevec, Glivec, and STI571) often becomes a barrier to the treatment of chronic myelogenous leukemia (CML). In order to identify markers of the action of imatinib mesylate, we used a mass spectrometry approach to compare protein expression profiles in human leukemia cells (K562) and in imatinib mesylate-resistant human leukemia cells (K562-R) in the presence and absence of imatinib mesylate. We identified 118 differentially regulated proteins in these two leukemia cell-lines, with and without a $1\;{\mu}M$ imatinib mesylate challenge. Nine proteins of unknown function were discovered. This is the first comprehensive report regarding differential protein expression in imatinib mesylate-treated CML cells.

• The Korean Journal of Pain
• /
• v.2 no.1
• /
• pp.61-65
• /
• 1989

Chloroma is a localized myeloblastic tumor which may develop during the course of myelogenous leukemia or as a presenting sign of the disease. A 47-year-old female diagnosed as chronic myelogenous leukemia in her hematologic remission period complained of left lower leg pain. The lumbar-spine series showed multiple osteolytic changes in the left lateral border of the lumbar spine. An inhomogenous soft tissue mass involving left lateral aspects of lumbar vertebrae was identified by CT-scanning. At the first pain attack, lumbar epidural steroid and local anesthetic injection could abolish her pain and the patient could go a few days without pain. The following radiation therapy could also improve the symptom and retain the pain free interval. One month later, a second pain attack occurred and lumbar and caudal epidural steroid and local anesthetic injections could result only in an incidental relief of pain. Radiation and chemotherapy were started but failed to relieve pain. A neurolytic block was considered but the patient's general condition was aggravated and even verbal communication with her became impossible.

• Journal of Chest Surgery
• /
• v.43 no.4
• /
• pp.466-469
• /
• 2010

We report here on a very rare case of granulocytic sarcoma of the pectoralis muscle on the left chest wall of a patient with chronic myelogenous leukemia, and this malady presented as a very rapidly growing hematoma-like mass.